Specialty-Pharma Launch Sequencing Board Adviser

The mandate

Three therapies addressing small, clinically complex populations may receive decisions within overlapping quarters, yet each plan assumes first call on the same field-medical talent, treatment-centre onboarding, evidence support and patient-navigation partners. The board lacks a neutral way to compare readiness when regulatory timing remains uncertain and disease teams use different milestone definitions. It must repeatedly decide whether to sequence, narrow, partner or preserve simultaneous launch options. The adviser brings operational commercialisation judgment to those decisions without forecasting approval outcomes.

Four days each month comprise one portfolio evidence review, one disease-team challenge, one chair or committee preparation session and one treatment-system or market visit. Five scheduled committee meetings are covered by the retainer, together with responses within two business days when a regulatory event changes sequence assumptions. The adviser will compare common evidence across all three therapies and preserve disease-specific constraints rather than force a single generic launch playbook.

The appointment spans nine months and ends after the board approves the following year’s launch-capacity allocation. The committee may extend for three months if one decision date moves beyond the current horizon, subject to a fresh independence statement and revised cadence. Renewal will not be presumed, and the adviser will close by transferring the comparative question set and decision history to the portfolio office.

The adviser has no line authority and carries no executive responsibility for regulatory strategy, medical affairs, market access, pricing, supply, patient services, promotion or country launches. Executives own readiness and directors reserve portfolio choices. The adviser may question whether evidence supports a claimed launch state, recommend sequencing conditions and request cross-therapy comparisons through the chair, but cannot approve materials, direct field teams, contact regulators or decide patient eligibility.

Relationships with competing therapy sponsors, patient organisations, treatment networks, contract commercialisation providers, access advisers, distributors or investors must be disclosed. A conflict involving a country or disease under review triggers screened information or recusal as the chair determines. Other non-competing appointments may continue if response capacity is protected. No success fee, investment position or prospective operating role may be tied to approval, launch priority, partnering or revenue outcome.

Why the board wants this voice

Disease teams are appropriately committed to their patients and programmes, which makes self-imposed deprioritisation unlikely even when shared capacity is finite. Functional executives see their own bottlenecks but not always the whole treatment-system path. The board wants someone who has sequenced complex launches across uncertainty and can challenge optimism without substituting for scientific, regulatory or access judgments.

What you will own

• Press each programme to evidence treatment-centre, diagnostic, medical, access, supply and patient-support readiness comparably.
• Test simultaneous-launch assumptions against shared expert capacity, country sequencing, partner limits and executive attention.
• Challenge milestone definitions that label plans ready while critical patient-system dependencies remain merely scheduled.
• Frame sequence, narrow, partner, delay and option-preservation choices with patient and enterprise consequences visible.
• Examine downside scenarios involving approval timing, label variation, reimbursement delay, constrained supply and slow centre activation.
• Maintain a cross-therapy assumption register, decision chronology, conflict record and conditions for board reconsideration.
• Shape a portfolio launch-governance discipline that management can continue after the advisory appointment closes.

Candidate qualifications

• Has governed multiple specialty or rare-disease launches competing for the same medical and commercialisation capabilities.
• Can evidence a sequencing recommendation made before approval certainty and explain how patient impact was considered.
• Understands treatment-centre activation, diagnosis pathways, medical education, market access, patient support and specialised supply.
• Has challenged confident disease teams while respecting regulatory, clinical, safety and promotional decision boundaries.
• Can compare readiness across therapies without erasing material differences in population, channel or country system.
• Is independent from relevant sponsors, patient vendors, treatment networks, investors and commercialisation service providers.

Non-negotiables

• Can attend five Zurich committee meetings and complete three agreed priority-market evidence visits.
• Will not predict regulatory decisions or present operational sequencing advice as clinical or access authority.
• Brings direct multi-launch specialty experience; broad pharmaceutical strategy without execution exposure is inadequate.
• Will disclose disease, sponsor, investor, patient-organisation and provider relationships before receiving programme materials.

1. 49 words maximum. Which shared capability has most often forced you to resequence specialty launches?
2. 49 words maximum. What current sponsor, provider, investor or patient-organisation relationship would require disclosure here?
3. 49 words maximum. How would you compare treatment-centre readiness across therapies with materially different patient pathways?